tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2013-1-41-46tumors-22Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL REPORTSЛУЧЕВАЯ ТЕРАПИЯ ПОСЛЕ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИ: КОГДА И ДЛЯ КОГО?Radiotherapy after radical prostatectomy: when and for whom?ДеньгинаН. В.Den’ginaN. V.indigo171201@yahoo.comПанченкоС. В.PanchenkoS. V.pan63ch@yandex.ruРодионовВ. В.RodionovV. V.dr.valery.rodionov@gmail.comГУЗ Областной клинический онкологический диспансер, г. Ульяновск. Ульяновский государственный университет, кафедра онкологии и лучевой диагностики.Russian Federation201320052015014146Copyright © Деньгина Н.В., Панченко С.В., Родионов В.В., 20152015Деньгина Н.В., Панченко С.В., Родионов В.В.Den’gina N.V., Panchenko S.V., Rodionov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/22

Радикальная простатэктомия способна обеспечить великолепный локальный контроль у больных с локализованным раком предстательной железы. Но части пациентов с отягощающими факторами (экстракапсулярное распространение опухоли (pT3a), инвазия семенных пузырьков (pT3b) или наличие опухолевых клеток в линии резекции (R1) и др.) потребуется проведение послеоперационной лучевой терапии. Наиболее дискутабельный вопрос касается сроков её проведения (непосредственно в послеоперационном периоде или отсроченно, при увеличении уровня PSA), а также критериев отбора кандидатов на это лечение. В статье рассматриваются аргументы «за» и «против» адъювантной лучевой терапии применимо к условиям и возможностям российских онкологических лечебных учреждений.

Radical prostatectomy can provide an excellent local control in patients with localized prostate cancer.  However, some patients with risk factors (extracapsular spread of tumor (pT3a), seminal vesicle invasion (pT3b) or the presence of tumor cells in the resection margin (R1), and others.) require postoperative radiation therapy. The most debated issue is the timing of radiotherapy (during postoperative period or delayed, or in case of increasing levels of PSA), as well as the criteria for the selection of candidates for this treatment. The article examines the arguments "pro" and "contra" adjuvant radiotherapy applicable to the conditions and possibilities of Russian oncological hospitals.

радикальная простатэктомияадъювантная лучевая терапияradical prostatectomyadjuvant radiotherapyReferencesHan M., Partin A. W., Pound C. R., Epstein J. I., Walsh P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. — 2001 Aug;Han M., Partin A. W., Pound C. R., Epstein J. I., Walsh P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. — 2001 Aug;(3): 555-65.(3): 555-65.Bottke D., de Reijke T. M., Bartkowiak D., Wiegel T. Salvage radiotherapy in patients with persisting / rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer 45:148-157, 2009.Bottke D., de Reijke T. M., Bartkowiak D., Wiegel T. Salvage radiotherapy in patients with persisting / rising PSA after radical prostatectomy for prostate cancer. Eur J Cancer 45:148-157, 2009.Bolla M., Van H. Poppel, Collette L. et al., Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). The Lancet, vol. 366, no. 9485, pp. 572-578, 2005.Bolla M., Van H. Poppel, Collette L. et al., Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). The Lancet, vol. 366, no. 9485, pp. 572-578, 2005.Thompson I. M., Tangen C. M., Paradelo J. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trialю Journal of the American Medical Association, vol. 296, no. 19, pp. 2329-2335, 2006.Thompson I. M., Tangen C. M., Paradelo J. et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trialю Journal of the American Medical Association, vol. 296, no. 19, pp. 2329-2335, 2006.Wiegel T., Bottke D., Steiner U. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02 / AUO AP 09 / 95. J Clin Oncol, vol. 27, no.18, pp. 2924-2930, 2009.Wiegel T., Bottke D., Steiner U. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02 / AUO AP 09 / 95. J Clin Oncol, vol. 27, no.18, pp. 2924-2930, 2009.Catton C., Gospodarowicz M., Warde P., Panzarella T., Catton P., McLean M., Milosevic M. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001 Apr; 59 (1): 51-60.Catton C., Gospodarowicz M., Warde P., Panzarella T., Catton P., McLean M., Milosevic M. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001 Apr; 59 (1): 51-60.Partin A. W., Oesterling J. E.. The clinical usefulness of prostate specific antigen: update. — 1994. J Urol. 1994; 152: 1358-68.Partin A. W., Oesterling J. E.. The clinical usefulness of prostate specific antigen: update. — 1994. J Urol. 1994; 152: 1358-68.Trabulsi E. J., Valicenti R. K., Hanlon A. L. et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. — 2008 Dec; 72 (6): 1298-302.Trabulsi E. J., Valicenti R. K., Hanlon A. L. et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology. — 2008 Dec; 72 (6): 1298-302.Fernando P. Secin, Caroline Savage, Claude Abbou et al. The Learning Curve for Laparoscopic Radical Prostatectomy: An International Multicenter Study. J Urol. — 2010, December; 184 (6): 2291-2296Fernando P. Secin, Caroline Savage, Claude Abbou et al. The Learning Curve for Laparoscopic Radical Prostatectomy: An International Multicenter Study. J Urol. — 2010, December; 184 (6): 2291-2296Stephenson A. J., Scardino P. T., Kattan M. W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. — 2007; 25: 2035-41.Stephenson A. J., Scardino P. T., Kattan M. W. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. — 2007; 25: 2035-41.Bianco F. J. Jr, Scardino P. T., Eastham J. A.. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function («trifecta»). Urology. — 2005; 66: 83-94.Bianco F. J. Jr, Scardino P. T., Eastham J. A.. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function («trifecta»). Urology. — 2005; 66: 83-94.Pound C. R., Partin A. W., Eisenberger M. A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. — 1999; 281: 1591-1597.Pound C. R., Partin A. W., Eisenberger M. A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. — 1999; 281: 1591-1597.Collette L., vsn Poppel H., Bolla M. et al. Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911) Eur J Cancer 41: 2662-2672, 2005.Collette L., vsn Poppel H., Bolla M. et al. Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911) Eur J Cancer 41: 2662-2672, 2005.Gregory P. Swanson, Joseph W. Basler. Prognostic Factors for Failure after Prostatectomy. J Cancer 2011; 2: 1-19.Gregory P. Swanson, Joseph W. Basler. Prognostic Factors for Failure after Prostatectomy. J Cancer 2011; 2: 1-19.

The authors declare that there are no conflicts of interest present.